PET scan use for NSCLC varies by demographic subgroup

This article originally appeared here.
Share this content:
Demographic Variation in Early PET Scan Use for NSCLC
Demographic Variation in Early PET Scan Use for NSCLC

(HealthDay News) -- For Medicare beneficiaries with non-small-cell lung cancer (NSCLC), demographic differences in the rates of positron emission tomography (PET) scan use persisted from 1998 to 2007, according to research published in the June issue of Radiology.

Michaela A. Dinan, Ph.D., from the Duke University Research Institute in Durham, N.C., and colleagues retrospectively analyzed Surveillance, Epidemiology and End Results Medicare data for 46,544 Medicare beneficiaries diagnosed with NSCLC (46,935 cases) between 1998 and 2007. Change in the number of PET examinations two months before to four months after diagnosis was the primary outcome measured.

The researchers found that, regardless of demographic subgroup, more than half of patients underwent one or more PET examinations by 2005. Patients who underwent PET were significantly more likely to be married, non-black, younger than 80 years, and to live in the Northeast or in census tracts with higher education levels, in multivariate analysis. Initially, living within 40 miles of a PET facility was significantly associated with undergoing PET, but by 2007, this association had disappeared. More rapid increases in imaging were seen among patients who were non-black, younger than 81 years, and who lived in the Northeast and South.

"PET imaging among Medicare beneficiaries with NSCLC was initially concentrated among non-black patients younger than 81 years," the authors write. "Despite widespread adoption among all subgroups, differences within demographic subgroups remained."

Several authors disclosed financial ties to the biopharmaceutical and technology industries.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs